Breast cancer remains one of the leading health issues, especially among women. Recent advancements in the treatment landscape have provided new hope to millions of patients worldwide. One such advancement came this week when the U.S. Food and Drug Administration (FDA) approved ribociclib—marketed as Kisqali—alongside endocrine therapy as an adjuvant treatment for early-stage high-risk breast
Health
Muscle-invasive bladder cancer (MIBC) remains a formidable challenge in oncology, often leading to poor outcomes despite aggressive treatment protocols. Traditionally, the standard of care has revolved around radical cystectomy combined with neoadjuvant chemotherapy, particularly for patients eligible for cisplatin-based regimens. However, this approach still leaves a significant proportion of patients—nearly half—with relapsed disease or mortality
The emergence of targeted therapies and immunotherapies has revolutionized the treatment landscape for various malignancies. Among these advancements is retifanlimab (Zynyz), a unique anti-PD-1 monoclonal antibody, which has recently shown significant potential in treating locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC). The results from a pivotal Phase III trial, presented
Menopause marks a significant transitional phase in a woman’s life, characterized not only by the cessation of menstrual cycles but also by physiological changes that can impact overall health. Among these changes, one of the most pressing is the increased risk of insulin resistance, which can lead to serious metabolic disorders such as diabetes, hyperglycemia,
The debate surrounding reproductive health continues to intensify, particularly with former President Donald Trump’s recent commitment to offer free in vitro fertilization (IVF) treatments. While this initiative targets affordability in reproductive healthcare, it has sparked considerable backlash among various factions within the Republican Party. Critics argue that this policy could shift the party’s stance on
A recent phase III trial revealed disappointing results regarding the use of mirtazapine, an inexpensive antidepressant, in alleviating severe, persistent breathlessness in patients suffering from chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The study, led by Irene Higginson, BMBS, PhD, from Kings College London, found that after 56 days of treatment, patients
The current organ transplant system in the United States is plagued with numerous problems that were brought into the limelight during a recent House Energy & Commerce Oversight and Investigations Subcommittee hearing. Testimonies shared during the hearing painted a grim picture of the organ procurement and transplantation process, highlighting issues such as supposedly deceased organ
CAR T-cell therapy, a promising immunotherapy approach for cancer treatment, has recently come under scrutiny regarding the risk of developing second primary malignancies (SPM). A systematic literature review and meta-analysis conducted by Kai Rejeski, MD, and colleagues shed light on this issue. The analysis included 5,517 patients with a median follow-up of 21.7 months, revealing
Childhood obesity is a growing concern worldwide, with significant implications for both the physical and psychological well-being of affected individuals. In a recent phase IIIa trial known as SCALE Kids, researchers evaluated the efficacy of liraglutide (Saxenda) in combination with lifestyle intervention for reducing body mass index (BMI) in young children with obesity. The results
The use of perioperative nivolumab in the treatment of non-small cell lung cancer (NSCLC) has shown promising results in reducing the risk of disease recurrence and death in post-surgical patients. An analysis of two phase III trials has revealed significant benefits in combining perioperative nivolumab with chemotherapy compared to neoadjuvant nivolumab and chemotherapy alone. The